Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleInvited Perspectives

Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer

Dik Kwekkeboom
Journal of Nuclear Medicine July 2016, 57 (7) 1002-1003; DOI: https://doi.org/10.2967/jnumed.115.171363
Dik Kwekkeboom
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 57 no. 7 1002-1003
DOI 
https://doi.org/10.2967/jnumed.115.171363
PubMed 
26912426

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication February 5, 2016
  • Accepted for publication February 8, 2016
  • Published online July 1, 2016.

Article Versions

  • previous version (February 18, 2016 - 10:23).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

Statistics from Altmetric.com

Cited By...

  • 6 Citations
  • 4 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
    Harshad R. Kulkarni, Aviral Singh, Christiane Schuchardt, Karin Niepsch, Manal Sayeg, Yevgeniy Leshch, Hans-Juergen Wester, Richard P. Baum
    Journal of Nuclear Medicine 2016 57 Supplement 3
  • Imaging and dosimetry for radium-223: the potential for personalized treatment
    Glenn D Flux
    The British Journal of Radiology 2017 90 1077
  • PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies
    Giampiero Giovacchini, Elisabetta Giovannini, Rossella Leoncini, Mattia Riondato, Andrea Ciarmiello
    European Journal of Nuclear Medicine and Molecular Imaging 2017 44 10
  • Formulation of clinical-scale 177 Lu-PSMA-617: From laboratory to clinics
    Tapas Das, Mohini Guleria, Sharmila Banerjee
    Nuclear Medicine and Biology 2016 43 12

Article usage

Article usage: February 2016 to December 2022

AbstractFullPdf
Feb 20160083
Mar 201650105
Apr 20164027
May 20164030
Jun 20167032
Jul 201664280194
Aug 201612239109
Sep 20161217471
Oct 20161212849
Nov 2016123727
Dec 2016125723
Jan 201766730
Feb 2017107653
Mar 201778034
Apr 2017174538
May 201733021
Jun 2017153526
Jul 2017172116
Aug 2017183014
Sep 2017173918
Oct 2017104023
Nov 2017173517
Dec 2017162911
Jan 201818288
Feb 2018152310
Mar 2018153514
Apr 201814318
May 201814236
Jun 201813116
Jul 20181695
Aug 201814178
Sep 201817911
Oct 201824155
Nov 2018252510
Dec 201825238
Jan 2019262010
Feb 201928195
Mar 2019391815
Apr 201927207
May 201919126
Jun 2019101510
Jul 2019271312
Aug 201914107
Sep 2019151513
Oct 2019241611
Nov 2019271312
Dec 20191988
Jan 202019157
Feb 202019189
Mar 2020231310
Apr 20201067
May 202016119
Jun 20201485
Jul 2020351
Aug 202026185
Sep 202011114
Oct 202019218
Nov 202015105
Dec 2020131510
Jan 20210136
Feb 2021066
Mar 20210185
Apr 20210126
May 20210167
Jun 202101611
Jul 202101812
Aug 20210103
Sep 2021037
Oct 202101117
Nov 202101917
Dec 20210164
Jan 2022094
Feb 2022041
Mar 202201910
Apr 20220910
May 2022098
Jun 20220127
Jul 20220173
Aug 20220166
Sep 2022099
Oct 2022087
Nov 20220116
Dec 2022094
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 57 (7)
Journal of Nuclear Medicine
Vol. 57, Issue 7
July 1, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
Dik Kwekkeboom
Journal of Nuclear Medicine Jul 2016, 57 (7) 1002-1003; DOI: 10.2967/jnumed.115.171363

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
Dik Kwekkeboom
Journal of Nuclear Medicine Jul 2016, 57 (7) 1002-1003; DOI: 10.2967/jnumed.115.171363
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
  • Google Scholar

More in this TOC Section

  • Could FAP-targeted molecular imaging replace FDG for standard-of-care oncologic PET?
  • Extravasation of diagnostic radiopharmaceuticals, a wolf in sheep's clothing?
  • Tau PET Visual Reads: Research and Clinical Applications and Future Directions
Show more Invited Perspectives

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire